Core Insights - The chairman of Jilin Tianzheng Biotechnology Co., Ltd., Cai Tiyuan, was awarded the title of Outstanding Private Entrepreneur in Jilin Province for his significant contributions in industrial development, technological innovation, and social responsibility [1][4]. Company Overview - Jilin Tianzheng Biotechnology was established in 2008 and has grown from Jiaohe into a comprehensive enterprise involved in the research, production, and sales of gelatin and its derivatives [1]. - The company has a registered capital of 113 million yuan and total assets of 450 million yuan, with an annual production capacity of 10,000 tons of bone gelatin, 3,000 tons of collagen peptides, and 35,000 tons of calcium hydrogen phosphate [1]. - The company's products are distributed nationwide and exported abroad, achieving a domestic market share of 12.02% [1]. Management Philosophy - Cai Tiyuan adheres to the management philosophy of "doing things based on one's duties and relying on abilities," which has guided the company's operations [4]. - Under his leadership, the company has been recognized as one of the top 100 private enterprises in Jilin Province and has received accolades for quality and integrity in business practices [4]. Community Engagement - As a representative in the Jilin City People's Congress, Cai Tiyuan has built a bridge between government and enterprises, actively promoting rural revitalization through industry chain integration [5]. - He has also been appointed as the honorary president of the Jiaohe Youth Entrepreneurs Association, supporting youth entrepreneurship and embodying the entrepreneurial spirit of responsibility [5].

Core Viewpoint - Guoen Technology is set to launch its global offering on January 27, with a pricing range of HKD 34-42 per share, aiming for a total issuance scale of approximately HKD 10.2 billion to 12.6 billion. The market is discussing the rationality of its pricing, stock price stability post-listing, and long-term valuation logic due to various factors including its business structure and competitive landscape [1][4][11]. Group 1: Financial Performance - Guoen Technology's revenue for 2022-2024 is projected at CNY 134 billion, CNY 174 billion, and CNY 192 billion, with a compound annual growth rate (CAGR) of 19.6%. However, growth is expected to slow to 9.9% in the first ten months of 2025 [2][3]. - The company's net profit has shown significant volatility, with figures of CNY 6.6 billion, CNY 4.7 billion, CNY 6.9 billion, and CNY 7.1 billion for the same periods, reflecting fluctuations of 3.1%, -29.7%, 45.2%, and 40.2% respectively [2][3]. Group 2: Cost Structure and Profitability - Raw material costs account for over 90% of sales costs, leading to limited profitability. The gross margin has declined from 11.8% to 8.3% from 2022 to 2024, with a slight recovery to 10.4% in the first three quarters of 2025 [3][11]. - The health sector shows stronger profitability potential, with a gross margin of 22.5% in the first ten months of 2025, but its revenue contribution is only 3.5%, insufficient to offset the low margins from the chemical sector [3][11]. Group 3: Market Position and Investor Interest - Guoen Technology's market capitalization of CNY 151 billion is the smallest among five concurrent A to H projects, which may reduce its attractiveness to institutional investors [4][5]. - The company has attracted eight cornerstone investors, raising USD 4.1 million, with significant investments from local and health-focused entities, indicating a strategic interest in its health sector [6][8]. Group 4: Market Dynamics and Risks - The absence of a greenshoe option in the offering raises concerns about stock price stability post-listing, as it lacks market support mechanisms [9][10]. - The Hong Kong market's preference for high-growth sectors may limit Guoen Technology's valuation, as its chemical business faces inherent valuation discounts compared to high-margin sectors [11].

Group 1 - The core viewpoint of the news is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription rate of 878 times [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and has a total fundraising target of up to 1.26 billion HKD [1] - The company has attracted eight cornerstone investors, raising a total of approximately 320 million HKD [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand, as well as the second-largest domestic brand in the hollow capsule industry, according to Frost & Sullivan [2] - Financially, the company reported revenues of approximately 13.406 billion RMB, 17.439 billion RMB, 19.188 billion RMB, and 17.444 billion RMB for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately 1.058 billion HKD, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds [3]

Group 1 - The core viewpoint of the article is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription of 878 times the public offering amount [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and a total fundraising target of up to HKD 1.26 billion [1] - The company has attracted eight cornerstone investors, with a total subscription amount of approximately HKD 320 million [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand in terms of production volume, as well as the second-largest domestic brand in the hollow capsule industry [2] - Financially, the company reported revenues of approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately HKD 1.058 billion, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds and general corporate purposes [3]

Core Viewpoint - The Hong Kong IPO market is experiencing a surge in demand, with Guoen Technology Co., Ltd. (referred to as "Guoen") launching its H-share offering, indicating strong investor interest and confidence in the company's growth potential [1][4]. Group 1: IPO Details - Guoen's H-share offering consists of 30 million shares, with approximately 10% allocated for public sale in Hong Kong and 90% for international investors [1]. - The price range for the H-share issuance is set between HKD 34 and HKD 42, with the public offering portion exceeding HKD 3.3 billion and an oversubscription rate of nearly 30 times [1][4]. Group 2: Investor Confidence - The cornerstone investor lineup for Guoen's IPO includes prominent institutions such as Liguan Investment, SLD International, and Luminous Horizon, collectively planning to subscribe for approximately HKD 320 million of the offering [4][5]. - The backing from these institutional investors reflects a strong market perception of Guoen's long-term value and growth prospects [5]. Group 3: Company Strengths - Guoen is recognized as the second-largest producer of organic polymer modified materials and organic polymer composite materials in China, and the largest producer of polystyrene by capacity [7]. - The company serves major clients in the home appliance, automotive, and new energy sectors, including Hisense, Midea, BYD, and CATL [7]. - In the health sector, Guoen controls Dongbao Biological, covering the entire industrial chain from gelatin raw materials to hollow capsules, ranking second in bone gelatin production and second among domestic brands in hollow capsule production in China [7]. Group 4: Fund Utilization - Guoen plans to allocate approximately 50% of the raised funds to establish a new production base in Thailand to expand capacity, while 35% will be used to enhance the production capacity of its Yixing facility [9]. - This strategic expansion aligns with the trend of downstream industries, such as home appliances and automotive, moving overseas, thereby opening new growth opportunities for the company [9].

Core Viewpoint - Guoen Technology (02768.HK) plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, aiming for a price range of HKD 34.00 to 42.00 per share, with trading expected to commence on February 4, 2026 [2][3] Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [3] - The company operates in two main sectors: the large chemical sector, providing solutions to manufacturers in automotive, new energy, and home appliances, and the health sector, supplying raw materials for supplements and pharmaceuticals [3][4] Market Position - In the large chemical industry, Guoen is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, holding a market share of 2.5% as of 2024 [4] - Guoen is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Financial Performance - The company has shown strong revenue growth, with revenues of RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate (CAGR) of 19.6% from 2022 to 2024 [7] - The sales figures for the fiscal years 2023 and 2024 indicate year-on-year growth rates of 30.1% and 10.0%, respectively [7] Market Trends - The market for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion by 2024, with a CAGR of 15.7% [8] - The market is expected to continue strong growth, reaching RMB 1,037.5 billion by 2029, with a forecasted CAGR of 14.1% from 2025 to 2029 [8] Use of Proceeds - The net proceeds from the share offering are estimated at approximately HKD 1.057 billion, with plans to allocate 50% for establishing a new production base in Thailand, 35% for expanding capacity in Yixing, and 10% for investments in Hong Kong [9]

Group 1 - The core viewpoint of the news is that Guoen Technology (国恩科技) is preparing for its IPO in the Hong Kong market, with a strong foundation and significant fundraising expectations [2][4] - Guoen Technology plans to globally issue approximately 30 million H-shares, with 3 million shares allocated for public offering in Hong Kong and 27 million shares for international offering [2] - The expected net fundraising amount is approximately HKD 1.058 billion, with funds allocated for expanding production capacity in Thailand and China, as well as for operational purposes [2][4] Group 2 - Guoen Technology specializes in new chemical materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] - The company ranks second in the organic polymer modification and composite materials industry in China by sales revenue, with a market share of 2.5%, and is the largest producer of polystyrene in China [4] - In the health sector, Guoen Technology's subsidiary, Dongbao Biological, has established a complete layout from collagen raw materials to end products, becoming a comprehensive group in the health segment [4] Group 3 - For the fiscal years 2022 to 2024, Guoen Technology's revenues were RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, and RMB 0.721 billion [5] - The company has shown solid performance in its financial results, indicating a stable growth trajectory [5]

Core Viewpoint - The company, Guoen Technology (02768), is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for capacity expansion and operational purposes [1][5]. Group 1: Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry and has established a vertically integrated product line from collagen to end products [3]. - The company ranks second in China's bone gelatin production by output and is the leading domestic brand in this category as of 2024 [3]. - It is also the second-largest domestic brand in the hollow capsule production market by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with key investors including Liguang Investment and others [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations of 50% for expanding production capacity in Thailand, 35% for capacity expansion in China, 10% for investments in Hong Kong, and 5% for operational funds [5].

Company Overview - Guoen Co., Ltd. (002768) is undergoing a listing hearing on the Hong Kong Stock Exchange, sponsored exclusively by China Merchants Securities International. The company operates in two main segments: Advanced Chemicals (Chemical New Materials) and Health Products (Gelatin, Collagen, and related upstream and downstream products) [1] Advanced Chemicals Segment - The Advanced Chemicals segment focuses on the chemical new materials industry, offering products such as green petrochemical materials (e.g., aromatic olefins, styrene, polystyrene) and organic polymer modified materials and composites. These products serve downstream industries including automotive, new energy, and home appliances [1] - According to Frost & Sullivan, Guoen Co., Ltd. is the second largest company in China for organic polymer modified materials and organic polymer composites by sales revenue in 2024, holding a market share of 2.5%. It is also the largest producer of polystyrene in China by production capacity in 2024 [1] Health Products Segment - The Health Products segment focuses on the natural collagen industry, developing collagen peptide derivatives and end products through its subsidiary Dongbao Biological (300239). The primary customers are medical and pharmaceutical manufacturers [1] - Based on Frost & Sullivan's data, Guoen Co., Ltd. ranks as the second largest producer of bone gelatin in China by production volume in 2024, and it is the largest domestic brand in this category. Additionally, it is the second largest domestic brand in the hollow capsule production sector in China, according to 2024 production volume estimates [1] Market Outlook - The market for organic polymer modified materials and organic polymer composites in China is projected to grow from RMB 544.8 billion in 2024 to RMB 1,037.5 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.1% [2]

Company Overview - Guoen Technology is a Chinese supplier focused on new chemical materials and gelatin, collagen upstream and downstream products, serving the chemical and health industries [4] - The company engages in research, production, and sales of products for industrial and commercial use, with clients including manufacturers in automotive, new energy, and home appliances [4] - In the health sector, Guoen Technology's clients include medical and pharmaceutical manufacturers who use its products as raw materials for supplements and medications [4] Market Position - According to Frost & Sullivan, Guoen Technology is the second-largest organic polymer modified materials and organic polymer composite materials company in China by sales revenue, with a market share of 2.5% in 2024 [5] - The company is the largest polystyrene producer in China by production capacity in 2024 [5] - In the health sector, Guoen Technology is the second-largest bone gelatin producer in China by output and the largest domestic brand in the same category [5] Financial Performance - The company reported revenues of approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [6] - The net profit for the same periods was RMB 7.24 billion, RMB 5.4 billion, RMB 7.21 billion, and RMB 7.21 billion [7] - The return on equity for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 was 12.3%, 8.5%, 10.2%, and 9.5%, respectively [10] Industry Overview - The global polymer materials market is projected to grow from RMB 298.9 billion in 2020 to RMB 456.15 billion in 2024, with a compound annual growth rate (CAGR) of 11.1% [12] - China's polymer materials market is expected to expand from RMB 110.8 billion in 2020 to RMB 162.8 billion in 2024, with a CAGR of 10.1% [12] - The organic polymer modified materials and organic polymer composite materials market is anticipated to grow from RMB 84.81 billion in 2020 to RMB 150.38 billion in 2024, with a CAGR of 15.4% [14]